References
- . Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347(17):1342–1349
- . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
- . American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
- . Rodbard HW, Jellinger PS, Bloomgarden ZT, . AACE/ACE glycemic control algorithm consensus panel. Endocr Pract. 2009;15(6):541–559
- . Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145(2):125–134
- . Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174–183
- . Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract. 2005;18(3):199–204
- . White JR Jr, Campbell RK, Hirsch IB. Novel insulins and strict glycemic control: analogues approximate normal insulin secretory response. Postgrad Med. 2003;113(6):30–36
- . Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32( 1 suppl):9S–18S
- . Meece J. Effect of insulin pen devices on the management of diabetes mellitus. Am J Health Syst Pharm. 2008;65(11):1076–1082
- . Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116(4):223–229
- . Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P; INS-2061 Study Team.Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care. 2003;26(8):2238–2243
- . Rosenstock J. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone. 2001;4(2):50–64
- . Raskin P, Allen E, Hollander P, ; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265
- . Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259
- . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881–885
- . Chase HP, Lockspeiser T, Peery B, . The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care. 2001;24(3):430–434
- . Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29(8):1812–1817
- . Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31(1):20–25
- . Fritsche A, Larbig M, Owens D, Häring HU; GINGER study group.Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010;12(2):115–123